Explore News By Topic
03/31/2016
INHIBITING PROTEIN COULD OFFER NEW HOPE FOR LETHAL PROSTATE CANCER, NEW PCF STUDY SHOWS
March 31, 2016 - A protein called N-Myc that is overexpressed in neuroendocrine prostate cancer (NEPC) may actually drive its progression, and its disruption causes a reduction in tumor growth, reports a new study by Lori Milken - PCF Young Investigator John Kyung Lee, MD of the University of California,... Read More
01/08/2016
Lands’ End launches Blue Oxford campaign to help raise funds for the Prostate Cancer Foundation
LANDS’ END LAUNCHES BLUE OXFORD CAMPAIGN TO HELP RAISE FUNDS FOR THE PROSTATE CANCER FOUNDATION Lands’ End Declares January 13 Blue Oxford Day DODGEVILLE, WIS. January 8, 2016 -- Lands’ End is launching the Blue Oxford campaign, an initiative created to help raise awareness and support for the Prostate Cancer... Read More
01/05/2016
Family History Of Prostate Cancer Tied To Heightened Risk Of Disease
TUESDAY, Jan. 5, 2016 -- A new study by PCF researcher Lorelei Mucci, ScD, reports new evidence for the "significant heritability" of prostate cancer. Her exciting results, published in the January 5 issue of The Journal of the American Medical Association, provide a new, compelling reason for men to get... Read More
10/28/2015
Landmark Trial Shows Same Drug Effective In Ovarian, Prostate Cancer
Oct. 28, 2015 -- A major new trial, funded in part by the Prostate Cancer Foundation (PCF), has concluded that a pioneering drug—Olaparib—developed to treat women with inherited cancers can also benefit men with certain types of advanced prostate cancer. These exciting results were published today by the study's leaders... Read More
10/22/2015
PROSTATE CANCER FOUNDATION AWARDS OVER $3.8 MILLION TO EARLY CAREER SCIENTISTS
SANTA MONICA, CA Oct. 22, 2015 – The Prostate Cancer Foundation (PCF) announced 19 new Young Investigator (YI) Awards at the 22nd Annual Scientific Retreat in Washington, DC, held October 8-10, 2015. Awardees were selected from a pool of 107 applicants from 65 institutions in 9 countries. To date, PCF... Read More
08/04/2015
6 New Movember Foundation – PCF Challenge Awards Advance Precision Medicine and Novel Treatments for Lethal Prostate Cancer
Nearly $7 Million to Fund Lifesaving Research SANTA MONICA, CA August 4, 2015 -- The Prostate Cancer Foundation (PCF) announces that it has received nearly $7 million from the Movember Foundation, a valued partner since 2007. These funds were made possible by the 2014 Movember U.S. Campaign and will support... Read More
06/19/2015
EARLIER CHEMOTHERAPY MAY EXTEND PATIENT SURVIVAL IN MULTIPLE PROSTATE CANCER SETTINGS
June 19, 2015 -- Chemotherapy has traditionally been used to treat prostate cancer patients only after they have developed resistance to hormone therapy. However, two new studies presented at the 2015 American Society for Clinical Oncology (ASCO) Annual Meeting found that the addition of taxane chemotherapy extended survival in several... Read More
06/16/2015
Prostate Cancer Foundation Steps Into The Ring To Knock Out Prostate Cancer For Good
Taps boxing legend Evander Holyfield and communications firm (add)ventures to produce public service announcement aimed at African-American men PR Newswire, SANTA MONICA, CA (June 16, 2015) -- The Prostate Cancer Foundation is throwing a one-two punch to knock out prostate cancer for good with the recent production of a public... Read More
06/02/2015
THE DISCOVERY OF NEW MOLECULAR MECHANISMS THAT MAY LINK OBESITY AND HIGH RISK PROSTATE CANCER
What this means for patients: Obesity is a known risk factor for prostate cancer, but the reasons for this remain unknown. This study identifies expression of chromatin remodeling genes as a likely mechanism linking these processes, and may lead to the development of therapies for obesity-related prostate cancer. June 2,... Read More
05/26/2015
The PARP-inhibitor Olaparib may be the first precision medicine therapy to reach prostate cancer patients
What this means for patients: A Phase II clinical trial found that up to one-third of metastatic prostate cancer patients have mutations in genes that control DNA repair in their tumors, causing them to selectively respond to treatment with olaparib. This therapy was recently approved for ovarian cancer patients who... Read More